Conbercept Treatment for Heart-Shaped Vascular Intertwined Nets in Macular Neovascularization: Anti-VEGF Drug Therapy Strategy Based on Vascular Geometry Diagnosed by OCTA. [PDF]
Clin Case RepMacular neovascularization (MNV), a hallmark of several retinal disorders including ocular trauma and wet age‐related macular degeneration, remains a major cause of vision impairment due to the proliferation of abnormal, fragile blood vessels.
Ou S, Shi F, Cai M, Wu Y.
europepmc +6 more sources
Two-year outcomes of intravitreal conbercept therapy for polypoidal choroidal vasculopathy [PDF]
BMC OphthalmologyBackground This study aims to evaluate the two-year outcomes of polypoidal choroidal vasculopathy (PCV) treated with conbercept and to investigate the predictive response factors.
Yang Liu +4 more
doaj +5 more sources
Intravitreal conbercept for chronic central serous chorioretinopathy with occult CNV: a retrospective clinical study based on multimodal ophthalmic imaging. [PDF]
Front Med (Lausanne)Purpose This study aimed to evaluate the therapeutic efficacy and safety of intravitreal conbercept in patients with chronic central serous chorioretinopathy (cCSC) complicated by occult choroidal neovascularization (CNV), and to explore its potential in
Wang S, Li J, Yan Z, Jiang Q, Li K.
europepmc +5 more sources
Intravitreal Double-Dose Conbercept Injection for the Treatment of Neovascular Age-Related Macular Degeneration: A Pilot Real-Life Clinical Practice Study. [PDF]
Clin OphthalmolPurpose To evaluate the efficacy and safety of conbercept for neovascular age-related macular degeneration (nAMD) when administered at the labeled dose (0.5 mg) and double dose (1.0 mg).
Qian T +6 more
europepmc +5 more sources
Conbercept for patients with age-related macular degeneration: a systematic review [PDF]
BMC Ophthalmology, 2018 Background Conbercept is a novel vascular endothelial growth factor (VEGF) inhibitor for the treatment of wet age-related macular degeneration (AMD). This systematic review aims to assess the efficacy and safety of conbercept in the treatment of wet AMD.
Jiaxing Zhang +7 more
doaj +4 more sources
Preoperative Intravitreal Conbercept Injection Reduced Both Angiogenic and Inflammatory Cytokines in Patients With Proliferative Diabetic Retinopathy. [PDF]
J Diabetes ResAims: To investigate the impact of intravitreal injection of conbercept, a recombinant fusion protein with decoy receptors for the vascular endothelial growth factor (VEGF) family, on intraocular concentrations of angiogenic and inflammatory mediators in
Huang Z +8 more
europepmc +3 more sources
Intravitreal conbercept injection with panretinal photocoagulation for high-risk proliferative diabetic retinopathy with vitreous hemorrhage. [PDF]
Int J OphthalmolAIM To assess the clinical efficacy and safety of combining panretinal photocoagulation (PRP) with intravitreal conbercept (IVC) injections for patients with high-risk proliferative diabetic retinopathy (HR-PDR) complicated by mild or moderate vitreous ...
Xu Y, Ye Q, Shen W.
europepmc +5 more sources
Efficacy and safety of intravitreal injections of conbercept for the treatment of idiopathic choroidal neovascularization [PDF]
BMC OphthalmologyBackground To determine the efficacy and safety of intravitreally injected conbercept, a vascular endothelial growth factor receptor fusion protein, for the treatment of idiopathic choroidal neovascularization (ICNV).
Gaixia Zhai +4 more
doaj +3 more sources
A Study on the Drug Concentration in Fellow Eyes After Unilateral Intravitreal Injection of Conbercept Into New Zealand Rabbit Eyes [PDF]
Frontiers in Pharmacology, 2021 Intravitreal injections of anti-vascular endothelial growth factor (VEGF) have become increasingly popular in the treatment of ocular diseases. However, few studies have determined the efficiency of unilateral intravitreal anti-VEGF injection in the ...
Yu Di, Haiyan Xu, Junjie Ye, Zijian Guo
doaj +2 more sources
Efficacy of conbercept after switching from bevacizumab/ranibizumab in eyes of macular edema secondary to central retinal vein occlusion [PDF]
International Journal of Ophthalmology, 2022 AIM: To explore the efficacy of conbercept after switching from bevacizumab/ranibizumab in eyes of central retinal vein occlusion (CRVO) through optical coherence tomography angiography (OCTA). METHODS: Patients with prior treatment of a minimum of three
Tong Zhao +4 more
doaj +2 more sources